To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - TR-1: Standard form for notification of major holdings

Release Date: 18/08/2022 16:00
Code(s): MEI     PDF:  
Wrap Text
TR-1: Standard form for notification of major holdings

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)

18 August 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details
   ISIN
   GB00B8HX8Z88

   Issuer Name
   MEDICLINIC INTERNATIONAL PLC

   UK or Non-UK Issuer
   UK

2. Reason for Notification
   An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation
   Name
   JPMorgan Chase & Co.
   City of registered office (if applicable)
   Country of registered office (if applicable)
   US

4. Details of the shareholder
   Name                              City of registered office Country of registered office
   J.P. Morgan Securities plc

5. Date on which the threshold was crossed or reached
   16-Aug-2022

6. Date on which Issuer notified
   18-Aug-2022

7. Total positions of person(s) subject to the notification obligation
                                 % of voting        % of voting rights   Total of both   Total number
                                 rights attached    through financial    in % (8.A +     of voting rights
                                 to shares (total   instruments (total   8.B)            held in issuer
                                 of 8.A)            of 8.B 1 + 8.B 2)

  Resulting                      3.512201           4.885164             8.397365        61909055
  situation on the
  date on which
  threshold was
  crossed or
  reached

  Position of                    2.909403           4.879603             7.789006
  previous
  notification (if
  applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of            Number of direct Number of indirect      % of direct       % of indirect
shares ISIN              voting rights    voting rights           voting rights     voting rights
code(if possible)        (DTR5.1)         (DTR5.2.1)              (DTR5.1)          (DTR5.2.1)

GB00B8HX8Z88                              25893486                                 3.512201
Sub Total 8.A
                         25893486                                 3.512201%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial        Expiration Exercise/conversion     Number of voting rights that        % of
instrument               date       period                  may be acquired if the              voting
                                                            instrument is                       rights
                                                            exercised/converted
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect
according to (DTR5.3.1R.(1) (b))
Type of             Expiration date Exercise/conversion  Physical or  Number of          % of voting
financial                           period               cash         voting rights      rights
instrument                                               settlement

Cash-               02/06/2023      02/06/2023           Cash          143409            0.019452
settled
Equity
Swap

Cash-               12/07/2023      12/07/2023           Cash          10861             0.001473
settled
Equity
Swap

Cash-               06/09/2023      06/09/2023           Cash          13795             0.001871
settled
Equity
Swap

Cash-               12/02/2024      12/02/2024           Cash          11913             0.001616
settled
Equity
Swap

Cash-               09/07/2029      09/07/2029           Cash          65281             0.008855
settled
Equity
Swap

Cash-               03/08/2027      03/08/2027           Cash          289               0.000039
settled
Equity
Swap

Cash-               06/07/2027      06/07/2027           Cash          309               0.000042
settled
Equity
Swap

Cash-              23/11/2022       23/11/2022           Cash          28558635          3.873703
settled
Equity
Swap

Cash-              09/08/2023       09/08/2023           Cash          759               0.000103
settled
Equity
Swap

Cash-              22/08/2023       22/08/2023           Cash          598               0.000081
settled
Equity
Swap

Cash-              01/02/2023       01/02/2023           Cash          16152             0.002191
settled
Equity
Swap

Cash-             22/02/2023        22/02/2023           Cash          117               0.000016
settled
Equity
Swap

Cash-             04/07/2023        04/07/2023           Cash          7193451           0.975722
settled
Equity
Swap

Sub Total 8.B2                                                         36015569          4.885164%

9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add
additional rows as necessary)
Ultimate           Name of         % of voting      % of voting rights    Total of both if it
controlling person controlled      rights if it     through financial     equals or is higher
                   undertaking     equals or is     instruments if it     than the notifiable
                                   higher than      equals or is higher   threshold
                                   the notifiable   than the notifiable
                                   threshold        threshold

JPMorgan           J.P. Morgan                      4.885164              7.119446%
Chase & Co.        Securities plc

JPMorgan           JPMorgan
Chase & Co.        Chase Bank,
                   National
                   Association

JPMorgan           J.P. Morgan
Chase & Co.        Equities
                   South Africa
                   Proprietary
                   Limited

JPMorgan           J.P. Morgan
Chase & Co.        Securities LLC

10. In case of proxy voting
    Name of the proxy holder

    The number and % of voting rights held

    The date until which the voting rights will be held

11. Additional Information
    Chain of controlled undertakings:

    JPMorgan Chase & Co.
    JPMorgan Chase Bank, National Association (100%)
    J.P. Morgan International Finance Limited (100%)
    J.P. Morgan Capital Holdings Limited (100%)
    J.P. Morgan Securities plc (100%)

    JPMorgan Chase & Co.
    JPMorgan Chase Bank, National Association (100%)

    JPMorgan Chase & Co.
    JPMorgan Chase Bank, National Association (100%)
    J.P. Morgan International Finance Limited (100%)
    J.P. Morgan Capital Holdings Limited (100%)
    J.P. Morgan Equities South Africa Proprietary Limited (100%)

    JPMorgan Chase & Co.
    JPMorgan Chase Holdings LLC (100%)
    J.P. Morgan Broker-Dealer Holdings Inc. (100%)
    J.P. Morgan Securities LLC (100%)
   
12. Date of Completion
    18-Aug-2022

13. Place Of Completion
    London

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day
case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three
of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four
of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle
East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient
beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital
in the Kingdom of Saudi Arabia in 2023.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor Relations
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 18-08-2022 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story